bromhexine has been researched along with 2019 Novel Coronavirus Disease in 15 studies
Bromhexine: A mucolytic agent used in the treatment of respiratory disorders associated with viscid or excessive mucus. (From Martindale, The Extra Pharmacopoeia, 30th ed, p744)
bromhexine : A substituted aniline that is 2,4-dibromoaniline which is substituted at position 6 by a [cyclohexyl(methyl)amino]methyl group. It is used (as the monohydrochloride salt) as a mucolytic for the treatment of respiratory disorders associated with productive cough (i.e. a cough characterised by the production of sputum).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Bromhexine is a potent inhibitor of transmembrane serine protease 2 and appears to have an antiviral effect in controlling influenza and parainfluenza infection; however, its efficacy in COVID-19 is controversial." | 3.30 | Effect of bromhexine in hospitalized patients with COVID-19. ( Babamahmoodi, A; Dastan, F; Eskandari, R; Jamaati, H; Marjani, M; Mulla, ZD; Tolouian, R, 2023) |
| "All patients had a confirmed 2019 novel coronavirus infection (COVID 19) based on a positive polymerase chain reaction (PCR) for SARS-CoV-2 virus RNA and/or a typical pattern of viral pneumonia on multispiral computed tomography." | 2.94 | [Results of Open-Label non-Randomized Comparative Clinical Trial: "BromhexIne and Spironolactone for CoronаvirUs Infection requiring hospiTalization (BISCUIT)]. ( Agapov, MA; Akopyan, ZA; Asratyan, DA; Begrambekova, YL; Bulanova, MM; Dyachuk, LI; Fuks, AA; Kamalov, АА; Mareev, VY; Mareev, YV; Matskeplishvili, ST; Mershina, ЕА; Orlova, YA; Pakhomov, PV; Pavlikova, EP; Plisyk, AG; Potapenko, AV; Samokhodskaya, LM; Seredenina, EM; Sinitsyn, VE, 2020) |
| " Using bromhexine at a dosage that selectively inhibits TMPRSS2 and, in so doing, inhibits TMPRSS2-specific viral entry is likely to be effective against SARS-CoV-2." | 2.66 | Potential new treatment strategies for COVID-19: is there a role for bromhexine as add-on therapy? ( de Villiers, D; Depfenhart, M; Di Somma, S; Lemperle, G; Meyer, M, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 15 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lu, D | 1 |
| Liu, D | 1 |
| Wang, X | 1 |
| Liu, Y | 2 |
| Ren, R | 1 |
| Pang, G | 1 |
| Wang, W | 1 |
| Zhou, Z | 1 |
| Ding, S | 1 |
| Yang, W | 1 |
| Jin, W | 1 |
| Chu, W | 1 |
| Xu, Z | 1 |
| Lipworth, B | 1 |
| Chan, R | 1 |
| Lipworth, S | 1 |
| RuiWen Kuo, C | 1 |
| Maggio, R | 1 |
| Corsini, GU | 1 |
| Habtemariam, S | 1 |
| Nabavi, SF | 1 |
| Ghavami, S | 1 |
| Cismaru, CA | 1 |
| Berindan-Neagoe, I | 1 |
| Nabavi, SM | 1 |
| Depfenhart, M | 1 |
| de Villiers, D | 1 |
| Lemperle, G | 1 |
| Meyer, M | 1 |
| Di Somma, S | 1 |
| Nitulescu, GM | 1 |
| Paunescu, H | 1 |
| Moschos, SA | 1 |
| Petrakis, D | 1 |
| Nitulescu, G | 1 |
| Ion, GND | 1 |
| Spandidos, DA | 1 |
| Nikolouzakis, TK | 1 |
| Drakoulis, N | 1 |
| Tsatsakis, A | 1 |
| Takano, H | 1 |
| Fu, Q | 1 |
| Zheng, X | 1 |
| Zhou, Y | 1 |
| Tang, L | 1 |
| Chen, Z | 1 |
| Ni, S | 1 |
| Wang, Y | 1 |
| Zhang, Y | 1 |
| Chen, X | 1 |
| Xue, K | 1 |
| Zhang, T | 1 |
| Ren, X | 1 |
| Mareev, VY | 2 |
| Orlova, YA | 2 |
| Pavlikova, EP | 2 |
| Matskeplishvili, ST | 2 |
| Akopyan, ZA | 2 |
| Plisyk, AG | 2 |
| Seredenina, EM | 2 |
| Asratyan, DA | 2 |
| Potapenko, AV | 2 |
| Malakhov, PS | 1 |
| Samokhodskaya, LM | 2 |
| Mershina, EA | 1 |
| Sinitsyn, VE | 2 |
| Bulanova, MM | 2 |
| Fuks, AA | 2 |
| Mareev, YV | 2 |
| Begrambekova, YL | 2 |
| Kamalov, AA | 1 |
| Agapov, MA | 1 |
| Dyachuk, LI | 1 |
| Mershina, ЕА | 1 |
| Pakhomov, PV | 1 |
| Kamalov, АА | 1 |
| Hörnich, BF | 1 |
| Großkopf, AK | 1 |
| Schlagowski, S | 1 |
| Tenbusch, M | 1 |
| Kleine-Weber, H | 1 |
| Neipel, F | 1 |
| Stahl-Hennig, C | 1 |
| Hahn, AS | 1 |
| Juul, S | 1 |
| Nielsen, EE | 1 |
| Feinberg, J | 1 |
| Siddiqui, F | 1 |
| Jørgensen, CK | 1 |
| Barot, E | 1 |
| Holgersson, J | 1 |
| Nielsen, N | 1 |
| Bentzer, P | 1 |
| Veroniki, AA | 1 |
| Thabane, L | 1 |
| Bu, F | 1 |
| Klingenberg, S | 1 |
| Gluud, C | 1 |
| Jakobsen, JC | 1 |
| Tolouian, R | 1 |
| Mulla, ZD | 1 |
| Jamaati, H | 1 |
| Babamahmoodi, A | 1 |
| Marjani, M | 1 |
| Eskandari, R | 1 |
| Dastan, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Low-dose Hydroxychloroquine and Bromhexine: a Novel Regimen for COVID-19 Prophylaxis in Healthcare Professionals (ELEVATE Trial)[NCT04340349] | Early Phase 1 | 214 participants (Anticipated) | Interventional | 2021-02-01 | Enrolling by invitation | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for bromhexine and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Potential new treatment strategies for COVID-19: is there a role for bromhexine as add-on therapy?
Topics: Betacoronavirus; Bromhexine; Coronavirus Infections; COVID-19; Expectorants; Humans; Pandemics; Pneu | 2020 |
Comprehensive analysis of drugs to treat SARS‑CoV‑2 infection: Mechanistic insights into current COVID‑19 therapies (Review).
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme 2; Betacoronavirus; Bromhexin | 2020 |
Interventions for treatment of COVID-19: Second edition of a living systematic review with meta-analyses and trial sequential analyses (The LIVING Project).
Topics: Adenosine Monophosphate; Adrenal Cortex Hormones; Alanine; Antibodies, Monoclonal, Humanized; Antivi | 2021 |
2 trials available for bromhexine and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
[Results of Open-Label non-Randomized Comparative Clinical Trial: "BromhexIne and Spironolactone for CoronаvirUs Infection requiring hospiTalization (BISCUIT)].
Topics: Bromhexine; Coronavirus Infections; COVID-19; Hospitalization; Humans; Prospective Studies; SARS-CoV | 2020 |
Effect of bromhexine in hospitalized patients with COVID-19.
Topics: Bromhexine; COVID-19; Humans; Patient Discharge; SARS-CoV-2; Treatment Outcome | 2023 |
10 other studies available for bromhexine and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Kinetics of Drug Molecule Interactions with a Newly Developed Nano-Gold-Modified Spike Protein Electrochemical Receptor Sensor.
Topics: Antiviral Agents; Bromhexine; COVID-19; Gold; Humans; Hydroxychloroquine; Kinetics; Ligands; Metal N | 2022 |
Degradation kinetics and formation of regulated and emerging disinfection by-products during chlorination of two expectorants ambroxol and bromhexine.
Topics: Ambroxol; Bromhexine; Bromine; Chlorides; Chlorine; COVID-19; Disinfectants; Disinfection; Expectora | 2023 |
Weathering the Cytokine Storm in Susceptible Patients with Severe SARS-CoV-2 Infection.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Age Factors; Angiotensin-Converting Enzyme Inhi | 2020 |
Repurposing the mucolytic cough suppressant and TMPRSS2 protease inhibitor bromhexine for the prevention and management of SARS-CoV-2 infection.
Topics: Antitussive Agents; Betacoronavirus; Bromhexine; Coronavirus Infections; COVID-19; Expectorants; Hum | 2020 |
Possible use of the mucolytic drug, bromhexine hydrochloride, as a prophylactic agent against SARS-CoV-2 infection based on its action on the Transmembrane Serine Protease 2.
Topics: Betacoronavirus; Bromhexine; Coronavirus Infections; COVID-19; Expectorants; Humans; Pandemics; Pneu | 2020 |
Pulmonary surfactant itself must be a strong defender against SARS-CoV-2.
Topics: Ambroxol; Angiotensin-Converting Enzyme 2; Bromhexine; Clinical Trials as Topic; COVID-19; COVID-19 | 2020 |
Re-recognizing bromhexine hydrochloride: pharmaceutical properties and its possible role in treating pediatric COVID-19.
Topics: Administration, Oral; Adolescent; Bromhexine; Child; Child, Preschool; Clinical Trials as Topic; COV | 2021 |
Evaluating the efficacy and safety of bromhexine hydrochloride tablets in treating pediatric COVID-19: A protocol for meta-analysis and systematic review.
Topics: Betacoronavirus; Bromhexine; Child; Coronavirus Infections; COVID-19; Expectorants; Humans; Meta-Ana | 2020 |
[Combination therapy at an early stage of the novel coronavirus infection (COVID-19). Case series and design of the clinical trial "BromhexIne and Spironolactone for CoronаvirUs Infection requiring hospiTalization (BISCUIT)"].
Topics: Betacoronavirus; Bromhexine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Hospitalizat | 2020 |
SARS-CoV-2 and SARS-CoV Spike-Mediated Cell-Cell Fusion Differ in Their Requirements for Receptor Expression and Proteolytic Activation.
Topics: Ambroxol; Amino Acid Substitution; Angiotensin-Converting Enzyme 2; Bromhexine; Cell Line; COVID-19; | 2021 |